Patron Exim Limited is an Ahmedabad-based entity primarily engaged in the **trading and distribution** of pharmaceutical raw materials, Active Pharmaceutical Ingredients (APIs), and a diverse range of industrial chemicals. Originally established as a partnership firm, **M/s Arvind Traders**, in **1982**, the company has undergone significant corporate restructuring, culminating in its listing on the **BSE SME Platform** in **March 2023**. While historically rooted in the pharmaceutical supply chain, the company is currently executing a strategic pivot toward **agricultural processing and edible oils**. --- ### **Corporate Evolution and Capital Structure** The company’s journey reflects a transition from a family-run partnership to a regulated public entity. | Date | Milestone | | :--- | :--- | | **April 1982** | Formation of **M/s Arvind Traders** (Partnership) | | **May 2015** | Strategic entry into **APIs** and Pharmaceutical Chemicals trading | | **August 2022** | Conversion to **Patron Exim Private Limited** | | **December 2022** | Conversion to **Patron Exim Limited** (Public) | | **March 2023** | **IPO** of **6,180,000** equity shares at **Rs. 27** per share (Total: **Rs. 16.69 crore**) | | **May 2024** | Relocation of Registered Office to **Empire Business Hub, Sola, Ahmedabad** | | **September 2025** | Formal amendment of MoA to include **Agro-processing and Manufacturing** | --- ### **Diversified Product Portfolio and Market Segments** Patron Exim operates as a critical intermediary in the chemical value chain, sourcing materials from manufacturers to supply retailers and semi-wholesalers. Its portfolio spans approximately **150 products**. #### **1. Pharmaceutical Raw Materials** The core of the business involves **Active Pharmaceutical Ingredients (APIs)**, excipients, and intermediates. These serve as the essential "bulk drugs" required for formulating finished dosages such as tablets, capsules, and liquids. #### **2. Industrial and Specialty Chemicals** The company maintains a broad footprint across several industrial verticals: * **Petrochemicals & Polymers:** Resins, plastics, and additives. * **Construction & Infrastructure:** Chemicals for foam, adhesives, plywood, and laminates. * **Process Industries:** Water treatment chemicals, oil and refinery chemicals, and food industry additives. * **Fine Chemicals:** Dyes, pigments, paints, and agro-chemicals. #### **3. Agricultural Expansion** As of **September 2025**, the company has expanded its mandate to include the **manufacturing, refining, and processing** of agricultural products and edible oils. Recent filings indicate that **Agro Product Sales** have become the primary revenue driver in the current fiscal period. --- ### **Operational Infrastructure and Quality Standards** The company operates a lean, trading-house model with no owned manufacturing plants, focusing instead on supply chain logistics and regulatory compliance. * **Quality Certifications:** The entity holds **ISO 9001:2015** (Quality), **ISO 22000:2018** (Food Safety), and **ISO 45001:2018** (Occupational Health & Safety). * **Industry Compliance:** Operations adhere to **WHO-GMP**, **HACCP**, and **HALAL** standards. * **Supply Chain Management:** Management emphasizes a "low product rejection rate" achieved through strategic supplier relationships and rigorous procurement protocols. * **Leadership:** Managed by **Narendrakumar Gangaramdas Patel** (Managing Director), who brings over **20 years** of experience in the pharmaceutical trading sector. --- ### **Financial Performance and Revenue Dynamics** The company’s financial profile is characterized by a recent shift in revenue sources and a complex balance sheet involving significant advances and investments. | Metric / Period | Value / Status | | :--- | :--- | | **H1 FY 2025-26 Revenue** | **Rs. 23.72 Crore** (Primarily Agro Product Sales) | | **FY 2023-24 Net Loss** | **Rs. 25.07 Lakh** | | **Advances to Suppliers** | **Rs. 558.29 Lacs** (as of Sept 30, 2025) | | **Investment Portfolio** | **Rs. 8.67 Crore** (Invested in Riya Patrochem and Solaris Agritech) | | **IPO Proceeds Status** | **No deviation** reported in utilization as of Sept 2025 | **Strategic Financial Limits:** Shareholders have authorized the Board to extend loans or guarantees up to **Rs. 50 crore** to support corporate growth and acquisitions. --- ### **Critical Risk Factors and Internal Control Lapses** Investors should note significant audit qualifications and regulatory challenges that impact the company’s risk profile. #### **1. Regulatory and Statutory Non-Compliance** * **Audit Trail:** The company failed to implement accounting software with a mandatory **non-disable audit trail (edit log)**, as required by **Section 128(5)** of the Companies Act, 2013. * **Internal Audit:** Lapses in conducting mandated internal audits for prior periods; **FY 2024-25** internal audit reports remain pending. * **Statutory Dues:** Outstanding unpaid liabilities include **Rs. 92.14 Lakh** in Income Tax and **Rs. 34.39 Lakh** in TDS/TCS. #### **2. Significant Litigations and Contingent Liabilities** The company is facing substantial financial claims that are not fully provided for in the books: * **GST Demand:** A **Rs. 21.98 Crore** demand related to **FY 2017-18** involving "suspicious sales" across group entities. * **Income Tax Dispute:** A demand of **Rs. 15.37 Crore** (plus **Rs. 2.61 Crore** interest) for **AY 2023-24**. #### **3. Asset Quality and Related Party Transactions** * **Related Party Loans:** **Rs. 16.16 Crore** advanced to **9 related parties** has remained outstanding for over **two years** without interest accrual. * **Doubtful Recoveries:** Approximately **Rs. 9.76 Crore** in advances to creditors are classified as doubtful, including **Rs. 4.21 Crore** from non-related parties. * **Operational Gaps:** Auditors noted a lack of physical inventory verification as of March 2025 and discrepancies between GST purchase data and internal books. --- ### **Strategic Outlook and Industry Drivers** Despite internal control challenges, Patron Exim seeks to capitalize on the growth of the Indian pharmaceutical and agricultural sectors: * **Government Support:** Leveraging the **INR 21,940 crore** PLI schemes for the pharmaceutical sector. * **Market Positioning:** Utilizing India’s status as a global hub for **generic drugs** and **US-FDA** compliant manufacturing to facilitate export-oriented trading. * **Diversification:** The pivot into **Agro-processing** represents an attempt to de-risk the business from pure pharmaceutical trading and tap into the high-volume agricultural commodities market.